Novartis Appoints New CEO
Novartis has appointed Dr. Vasant Narasimhan as CEO.
On Sept. 4, 2017, Novartis announced the appointment of Vasant Narasimhan, MD, as CEO of Novartis by its board of directors, effective Feb. 1, 2018. Dr. Narasimhan currently acts as the company’s global head of drug development, chief medical officer, and a member of the executive committee.
Dr. Narasimhan, who has been with the company since 2005, will replace Joseph Jimenez. Jimenez, who served in the position for 8 years, will be available for advising until his retirement on Aug. 31, 2018.
Source: Novartis
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
